<DOC>
	<DOCNO>NCT00258011</DOCNO>
	<brief_summary>This multi-center , open label , study conduct evaluate safety laronidase administer intravenous drip infusion Japanese patient MPS I disease . Following baseline evaluation , patient receive weekly infusion JC0498 intravenous dose 100 units/kg . Patient safety monitor continuously throughout trial . In addition , effect JC0498 treatment patient population assess periodically evaluate aspect MPS I disease patient schedule interval duration trial . Since patient may eligible trial receive JC0498 , portion data may capture retrospectively record onto case report form ( CRFs ) . This study represent first good clinical practice ( GCP ) effort characterize MPS I Japanese population evaluate effect JC0498 disease manifestation .</brief_summary>
	<brief_title>Study AldurazymeÂ® Replacement Therapy Patients With Mucopolysaccharidosis I ( MPS I ) Disease</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>Written inform consent/assent patient write informed consent parent ( ) legal guardian ( ) , depend age patient , require prior protocolrelated procedure perform ; include information regard hematopoietic stem cell transplantation ( HSCT ) order assure guardian ( ) fully inform regard risk benefit alternative treatment patient eligible trial severe manifestation MPS I neurodegeneration . Have clinical diagnosis MPS , confirm measurable clinical sign symptom MPS I . Have confirm iduronidase deficiency leukocyte alphaLiduronidase enzyme activity level le 10.0 % low limit normal range measure laboratory ( SRL ) The patient consideration previously undergone hematopoietic stem cell transplantation . The patient acute hydrocephalus time enrollment . The patient clinically significant organic disease ( exception symptom relate MPS I ) include : cardiovascular , hepatic , pulmonary , neurologic , renal disease , serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial potentially decrease survival . The patient receive investigational product within 30 day prior trial enrollment ( exception : JC0498 ) . The patient know severe hypersensitivity JC0498 component delivery solution .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>MPS I Disease</keyword>
</DOC>